233 related articles for article (PubMed ID: 17965736)
1. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
Takemasa H; Nagatomo T; Abe H; Kawakami K; Igarashi T; Tsurugi T; Kabashima N; Tamura M; Okazaki M; Delisle BP; January CT; Otsuji Y
Br J Pharmacol; 2008 Feb; 153(3):439-47. PubMed ID: 17965736
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Rajamani S; Eckhardt LL; Valdivia CR; Klemens CA; Gillman BM; Anderson CL; Holzem KM; Delisle BP; Anson BD; Makielski JC; January CT
Br J Pharmacol; 2006 Nov; 149(5):481-9. PubMed ID: 16967046
[TBL] [Abstract][Full Text] [Related]
3. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
4. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.
Kawakami K; Nagatomo T; Abe H; Kikuchi K; Takemasa H; Anson BD; Delisle BP; January CT; Nakashima Y
Br J Pharmacol; 2006 Mar; 147(6):642-52. PubMed ID: 16314852
[TBL] [Abstract][Full Text] [Related]
7. Propofol inhibits hERG K
Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
[TBL] [Abstract][Full Text] [Related]
8. The effects of a novel anti-arrhythmic drug, acehytisine hydrochloride, on the human ether-a-go-go related gene K channel and its trafficking.
Huang X; Yang Y; Zhu J; Dai Y; Pu J
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):145-54. PubMed ID: 19143746
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
10. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Ficker E; Obejero-Paz CA; Zhao S; Brown AM
J Biol Chem; 2002 Feb; 277(7):4989-98. PubMed ID: 11741928
[TBL] [Abstract][Full Text] [Related]
11. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
Bai YL; Liu HB; Sun B; Zhang Y; Li Q; Hu CW; Zhu JX; Gong DM; Teng X; Zhang Q; Yang BF; Dong DL
J Mol Cell Cardiol; 2011 Nov; 51(5):876-80. PubMed ID: 21820442
[TBL] [Abstract][Full Text] [Related]
12. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Obers S; Staudacher I; Ficker E; Dennis A; Koschny R; Erdal H; Bloehs R; Kisselbach J; Karle CA; Schweizer PA; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2010 May; 381(5):385-400. PubMed ID: 20229012
[TBL] [Abstract][Full Text] [Related]
13. Blockade of HERG and Kv1.5 by ketoconazole.
Dumaine R; Roy ML; Brown AM
J Pharmacol Exp Ther; 1998 Aug; 286(2):727-35. PubMed ID: 9694927
[TBL] [Abstract][Full Text] [Related]
14. HERG-F463L potassium channels linked to long QT syndrome reduce I(Kr) current by a trafficking-deficient mechanism.
Yang HT; Sun CF; Cui CC; Xue XL; Zhang AF; Li HB; Wang DQ; Shu J
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):822-7. PubMed ID: 19215240
[TBL] [Abstract][Full Text] [Related]
15. Blockage of hERG current and the disruption of trafficking as induced by roxithromycin.
Han SN; Yang SH; Zhang Y; Duan YY; Sun XY; Chen Q; Fan TL; Ye ZK; Huang CZ; Hu XJ; Zhang Z; Zhang LR
Can J Physiol Pharmacol; 2013 Dec; 91(12):1112-8. PubMed ID: 24289083
[TBL] [Abstract][Full Text] [Related]
16. Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. Human Ether-à-go-go-Related Gene.
Roti EC; Myers CD; Ayers RA; Boatman DE; Delfosse SA; Chan EK; Ackerman MJ; January CT; Robertson GA
J Biol Chem; 2002 Dec; 277(49):47779-85. PubMed ID: 12270925
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
[TBL] [Abstract][Full Text] [Related]
18. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
19. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
Hancox JC; Mitcheson JS
Br J Pharmacol; 2006 Nov; 149(5):457-9. PubMed ID: 16967047
[TBL] [Abstract][Full Text] [Related]
20. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
Guo J; Massaeli H; Li W; Xu J; Luo T; Shaw J; Kirshenbaum LA; Zhang S
J Pharmacol Exp Ther; 2007 Jun; 321(3):911-20. PubMed ID: 17377062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
